Antigen specificity of T lymphocytes from unstable human atherosclerotic plaques

Published: 27-02-2007
Last updated: 08-05-2024

In vitro characterization of T lymphocytes from human atherosclerotic lesions.

Ethical review	Approved WMO
Status	Pending
Health condition type	Coronary artery disorders
Study type	Observational non invasive

Summary

ID

NL-OMON30754

Source
ToetsingOnline

Brief title
T cells and atherosclerosis

Condition

- Coronary artery disorders
- Hepatobiliary neoplasms malignant and unspecified
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis

Synonym
atherosclerosis, coronary artery disease

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: acute myocardial infarction, antigens, Atherosclerosis, T-lymphocytes

Outcome measures

Primary outcome

Proliferation responses against different antigens of atherosclerotic plaque

derived T lymphocytes.

Secondary outcome

N.A.

Study description

Background summary

Atherosclerotic lesions are characterized by the presence of an inflammatory infiltrate, predominantly macrophages and T lymphocytes. Several lines of evidence have shown that local activation of T lymphocytes contributes to atherosclerotic plaque inflammation and the onset of acute cardiovascular complications. At present it is not clear which antigens are responsible for the activation of T lymphocytes in human atherosclerotic tissue, but antigens that have been suggested to play a role include lipoproteins and antigens from microbial origin. The aim of the present study is a functional characterization (including the antigen specificity) of T cells from unstable human atherosclerotic lesions.

Study objective

In vitro characterization of T lymphocytes from human atherosclerotic lesions.

Study design

Isolation of T lymphocytes from human atherosclerotic tissue, and further in vitro characterization. Because we want to increase the amount of tissue with which we can perform experiments, tissue will be collected at two diferent locations, the Slotervaart hospital and the AMC. Studies that will be perfomed with these specimens are similar to those that have already been published:
- de Boer et al, Cardiovasc Res. 2000 48: 402-8.

- de Boer et al, Atherosclerosis. 2006 184:322-9.

Study burden and risks

NA

Contacts

Public
Academisch Medisch Centrum

Meibergdreef 9
1105 AZ Amsterdam
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
1105 AZ Amsterdam
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Obstructive carotid artery disease (TIA), claudicatio intermittens

Exclusion criteria

Immunedeficiency, immunosuppressive therapy, sepsis

Study design

Design

Study type: Observational non invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Basic science

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-03-2007
Enrollment:	150
Type:	Anticipated

Ethics review

Approved WMO

Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL16045.018.07